

# GUIDELINES ON PENILE CANCER

*(Text update April 2014)*

O.W. Hakenberg (Chair), N. Watkin, E. Compérat, S. Minhas,  
A. Necchi, C. Protzel

## **Introduction and epidemiology**

The incidence of penile cancer increases with age, with an age peak during the sixth decade of life. However, the disease does occur in younger men. There are significant geographical variations within Europe as well as worldwide. Penile cancer is common in regions with a high prevalence of human papilloma virus (HPV), which may account for the global incidence variation as the worldwide HPV prevalence varies considerably.

There is at present no recommendation for the use of HPV vaccination in boys as this controversial.

## **Risk factors**

Recognized aetiological and epidemiological risk factors for penile cancer are:

Risk factors	Relevance
Phimosis	OR 11-16 vs. no phimosis
Chronic penile inflammation (balanoposthitis related to phimosis) Balanitis xerotica obliterans (lichen sclerosus)	Risk
Sporalene and UVA phototherapy for various dermatological conditions such as psoriasis	Incidence rate ratio 9.51 with > 250 treatments
Smoking	5-fold increased risk (95% CI: 2.0-10.1) vs. non-smokers
HPV infection condylomata acuminata	22.4% in verrucous SCC 36-66.3% in basaloid-warty
Rural areas, low socioeconomic status, unmarried	
Multiple sexual partners, early age of first intercourse	3-5-fold increased risk of penile cancer

*HPV = human papilloma virus; OR = odds ratio; SCC = squamous cell carcinoma; UVA = ultraviolet A.*

## Pathology

Squamous cell carcinoma in different variants accounts for more than 95% of cases of malignant penile disease. Table 1 lists premalignant lesions and Table 2 lists the pathological subtypes of penile carcinomas.

**Table 1: Premalignant penile lesions (precursor lesions)**

Lesions sporadically associated with SCC of the penis

- Cutaneous horn of the penis
- Bowenoid papulosis of the penis
- Lichen sclerosus (balanitis xerotica obliterans)

Premalignant lesions (up to one-third transform to invasive SCC)

- Intraepithelial neoplasia grade III
- Giant condylomata (Buschke-Löwenstein)
- Erythroplasia of Queyrat
- Bowen's disease
- Paget's disease (intradermal ADK)

**Table 2: Histological subtypes of penile carcinomas, their frequency and outcome**

Subtype	frequency (%)	prognosis
Usual SCC	48-65	Depends on location, stage and grade.
Basaloid carcinoma	4-10	Poor prognosis, frequently early inguinal nodal metastasis.
Warty carcinoma	7-10	Good prognosis, metastasis rare.
Verrucous carcinoma	3-8	Good prognosis, no metastasis.
Papillary carcinoma	5-15	Good prognosis, metastasis rare.
Sarcomatoid carcinoma	1-3	Very poor prognosis, early vascular metastasis.
Mixed carcinoma	9-10	Heterogenous group.

Pseudohyperplastic carcinoma	<1	Foreskin, related to lichen sclerosus, good prognosis, metastasis not reported.
Carcinoma cuniculatum	<1	Variant of verrucous carcinoma, good prognosis, metastasis not reported.
Pseudoglandular carcinoma	<1	High grade carcinoma, early metastasis, poor prognosis.
Warty-basaloid carcinoma	9-14	Poor prognosis, high metastatic potential, (higher than in warty, lower than in basaloid SCC).
Adenosquamous carcinoma	<1	Central and peri-meatal glans, high grade carcinoma, high metastatic potential but low mortality.
Mucoepidermoid carcinoma	<1	Highly aggressive, poor prognosis.
Clear cell variant of penile carcinoma	1-2	Exceedingly rare, associated with HPV, aggressive, early metastasis, poor prognosis, outcome lesion dependent, frequent lymphatic metastasis.

## Biopsy

In the management of penile cancer there is need for histological confirmation if:

- there is doubt about the exact nature of the lesion (e.g. CIS, metastasis or melanoma) and/or;
- treatment with topical agents, radiotherapy or laser surgery is planned.

## Staging and classification systems

The 2009, Tumour Node Metastasis (TNM) classification should be used (Table 3). A subclassification of the T2 category regarding invasion of the corpus spongiosum only, or the corpora cavernosa as well, would be desirable as it has been shown that the prognosis for corpus spongiosum invasion only is much better than for corpora cavernosa invasion.

**Table 3: 2009 TNM clinical and pathological classification of penile cancer**

### Clinical classification

#### T - Primary tumour

TX	Primary tumour cannot be assessed
T0	No evidence of primary tumour
Tis	Carcinoma <i>in situ</i>
Ta	Non-invasive carcinoma
T1	Tumour invades subepithelial connective tissue
T1a	Tumour invades subepithelial connective tissue without lymphovascular invasion and is not poorly differentiated or undifferentiated (T1G1-2)
T1b	Tumour invades subepithelial connective tissue with lymphovascular invasion or is poorly differentiated or undifferentiated (T1G3-4)
T2	Tumour invades corpus spongiosum and/or corpora cavernosa
T3	Tumour invades urethra
T4	Tumour invades other adjacent structures

#### N - Regional lymph nodes

NX	Regional lymph nodes cannot be assessed
N0	No palpable or visibly enlarged inguinal lymph node
N1	Palpable mobile unilateral inguinal lymph node

N2	Palpable mobile multiple unilateral or bilateral inguinal lymph nodes
N3	Fixed inguinal nodal mass or pelvic lymphadenopathy, unilateral or bilateral
<b>M - Distant metastasis</b>	
M0	No distant metastasis
M1	Distant metastasis
<b>Pathological classification</b>	
The pT categories correspond to the clinical T categories. The pN categories are based upon biopsy or surgical excision.	
<b>pN - Regional lymph nodes</b>	
pNX	Regional lymph nodes cannot be assessed
pN0	No regional lymph node metastasis
pN1	Intranodal metastasis in a single inguinal lymph node
pN2	Metastasis in multiple or bilateral inguinal lymph nodes
pN3	Metastasis in pelvic lymph node(s), unilateral or bilateral or extranodal extension of any regional lymph node metastasis
<b>pM - Distant metastasis</b>	
pM0	No distant metastasis
pM1	Distant metastasis
<b>G - Histopathological grading</b>	
GX	Grade of differentiation cannot be assessed
G1	Well differentiated
G2	Moderately differentiated
G3-4	Poorly differentiated/undifferentiated

## Diagnostic evaluation and staging

Penile cancer can be cured in over 80% of all cases if diagnosed early. Once metastatic spread has occurred, it is a

life-threatening disease with poor prognosis. Local treatment, although potentially life-saving, can be mutilating and devastating for the patient's psychological well-being.

### **Physical Examination**

Careful palpation of both groins for enlarged inguinal lymph nodes must be part of the initial physical examination of patients with penile cancer.

### **Imaging**

- Ultrasound can give information about infiltration of the corpora
- Magnetic resonance imaging (MRI) with an artificially induced erection can help to exclude tumour invasion of the corpora cavernosa if preservation of the penis is planned .
- In case of non-palpable inguinal nodes current imaging techniques are not reliable in detecting micro-metastases.
  - A pelvic CT scan can be used to assess pelvic lymph nodes.
  - In case of positive inguinal nodes, CT of the abdomen and pelvis and a chest X-ray are recommended; a thoracic CT will be more sensitive than an X-ray.

<b>Guidelines for the diagnosis and staging of penile cancer</b>	<b>GR</b>
<b>Primary tumour</b>	
Physical examination, recording morphology, extent and invasion of penile structures.	C
MRI with artificial erection in selected cases with intended organ-preserving surgery.	
<b>Inguinal lymph nodes</b>	
Physical examination of both groins, recording number, laterality and characteristics of inguinal nodes: <ul style="list-style-type: none"> <li>• If nodes are not palpable, invasive lymph node staging in high-risk patients;</li> <li>• If nodes are palpable, a pelvic CT may be indicated, PET/CT is an option.</li> </ul>	C
<b>Distant metastases</b>	
In N+ patients, an abdominopelvic CT scan and chest X-ray are required for systemic staging.	C
PET/CT scan is an option.	
In patients with systemic disease or with relevant symptoms, a bone scan may be indicated.	

*CT = computed tomography; GR = grade of recommendation; PET = positron emission tomography.*

## **Disease management**

Treatment of the primary penile cancer lesion aims to remove the tumour completely, while preserving as much of the penis as possible without compromising radicality.

<b>Guidelines for stage-dependent local treatment of penile carcinoma</b>			
<b>Primary tumour</b>	<b>Organ-preserving treatment whenever possible</b>	<b>LE</b>	<b>GR</b>
Tis	Topical treatment with 5-fluorouracil or imiquimod for superficial lesions with or without photodynamic control.	3	C
	Laser ablation with CO <sub>2</sub> or Nd:YAG laser.		
	Glans resurfacing.		
Ta, T1a (G1, G2)	Wide local excision with circumcision CO <sub>2</sub> or Nd:YAG laser surgery with circumcision.	3	C
	Laser ablation with CO <sub>2</sub> or Nd:YAG laser.		
	Glans resurfacing.		
	Glansectomy with reconstructive surgery, with or without skin grafting.		
	Radiotherapy by external beam or as brachytherapy for lesions < 4 cm.		
T1b (G3) and T2 confined to the glans	Wide local excision plus reconstructive surgery, with or without skin grafting.	3	C
	Laser ablation with circumcision.		
	Glansectomy with circumcision, with reconstruction.		

	Radiotherapy by external beam or brachytherapy for lesions < 4 cm in diameter.		
T2 with invasion of the corpora cavernosa	Partial amputation and reconstruction.	3	C
	Radiotherapy by external beam or brachytherapy for lesions < 4 cm in diameter.		
T3 with invasion of the urethra	Partial penectomy or total penectomy with perineal urethrostomy.	3	C
T4 with invasion of other adjacent structures	Neoadjuvant chemotherapy followed by surgery in responders. Alternative: palliative external beam radiation.	3	C
Local recurrence after conservative treatment	Salvage surgery with penis-sparing treatment in small recurrences or partial amputation.	3	C
	Large- or high-stage recurrence: partial or total amputation.	3	C

*CO<sub>2</sub>* = carbon dioxide; *GR* = grade of recommendation; *LE* = level of evidence; *Nd:YAG* = neodymium:yttrium-aluminium-garnet.

### Management of inguinal lymph nodes

The treatment of regional lymph nodes is crucial for the survival of the patient. A surveillance strategy carries considerable risk as regional lymph node recurrence dramatically reduces the chance of long-term survival. Invasive staging by modified inguinal lymphadenectomy or dynamic sentinel node biopsy is recommended for penile cancers pT1G1 and higher.

<b>Guidelines for treatment strategies for nodal metastases</b>			
<b>Regional lymph nodes</b>	<b>Management of regional lymph nodes is fundamental in the treatment of penile cancer</b>	<b>LE</b>	<b>GR</b>
No palpable inguinal nodes (cN0)	Tis, Ta G1, T1G1: surveillance.	2a	B
	> T1G2: invasive lymph node staging by bilateral modified inguinal lymphadenectomy or DSNB.	2a	B
Palpable inguinal nodes (cN1/cN2)	Radical inguinal lymphadenectomy.		
Fixed inguinal lymph nodes (cN3)	Neoadjuvant chemotherapy followed by radical inguinal lymphadenectomy in responders.		
Pelvic lymphadenectomy	Ipsilateral pelvic lymphadenectomy is indicated if two or more inguinal nodes are involved on one side (pN2) and in extracapsular nodal metastasis (pN3).	2a	B
Adjuvant chemotherapy	Indicated in pN2/pN3 patients after radical lymphadenectomy.	2b	B
Radiotherapy	Radiotherapy is not indicated for the treatment of nodal disease in penile cancer.		

GR = grade of recommendation; DSNB = dynamic sentinel node biopsy; LE = level of evidence.

<b>Guidelines for chemotherapy in penile cancer patients</b>	<b>LE</b>	<b>GR</b>
Adjuvant chemotherapy (3-4 cycles of TPF) is an option for patients with pN2-3 tumours.	2b	C
Neoadjuvant chemotherapy (4 cycles of a cisplatin and taxane-based regimen) followed by radical surgery is recommended in patients with non-resectable or recurrent lymph node metastases.	2a	B
Chemotherapy for systemic disease is an option in patients with limited metastatic load.	3	C

*GR = grade of recommendation; LE = level of evidence; TPF = cisplatin, 5-FU plus paclitaxel or docetaxel.*

## Follow-up

Follow-up after curative treatment in penile carcinoma as in any malignant disease is important for two reasons:

- early detection of recurrence allows for potentially curative treatment;
- the detection and management of treatment-related complications.

Local recurrence does not significantly reduce long-term survival if successfully treated while inguinal nodal recurrence leads to a drastic reduction in the probability of long-term disease-specific survival.

## Quality of life

Overall, nearly 80% of penile cancer patients of all stages can be cured. Partial penectomy has negative consequences for the patients' self-esteem and sexual function. Organ-preserving treatment allows for better quality of life and sexual function and should be offered to all patients whenever feasible. Referral to centres with experience is recommended

<b>Guidelines for follow-up in penile cancer</b>		
	<b>Interval of follow-up</b>	
	Years 1-2	Years 3-5
<i>Follow-up of the primary tumour</i>		
Penile preserving treatment	3 months	6 months
Amputation	3 months	1 year
<i>Follow-up of the inguinal lymph nodes</i>		
Surveillance	3 months	6 months
pN0 at initial treatment	3 months	1 year
pN+ at initial treatment	3 months	6 months

*CIS = carcinoma in situ; CT = computed tomography; GR = grade of recommendation; FNAB = fine-needle aspiration biopsy; FNAC = fine-needle aspiration cytology; MRI = magnetic resonance imaging; US = ultrasound.*

and psychological support is very important for penile cancer patients.

<b>Examinations and investigations</b>	<b>Maximum duration of follow-up</b>	<b>GR</b>
Regular physician or self-examination. Repeat biopsy after topical or laser treatment for CIS.	5 years	C
Regular physician or self-examination.	5 years	C
Regular physician or self-examination.	5 years	C
Regular physician or self-examination. US with FNAB optional.	5 years	C
Regular physician or self-examination. US with FNAC optional CT/MRI optional.	5 years	C

*This short booklet text is based on the more comprehensive EAU Guidelines (ISBN 978-90-79754-80-9), available to all members of the European Association of Urology at their website, <http://www.uroweb.org>.*